TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9543158
Drug: 75 IU
Normalized name: Follitropin Beta 75 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 IU daily from Day(LH+19) until Day(LH+23) (group B; n = 12)
Study: 2973849
Drug: hANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hANP infusion (2 pmol min‐1 kg‐1 for 3 h)
Study: 20862469
Drug: Half-dose gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose gadolinium contrast
Study: 20862469
Drug: Full-dose gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose gadolinium contrast
Study: 18442632
Drug: Calorie restriction
Normalized name: Resurrection Lily Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie restriction mimetic therapy with metformin for 3 years
Study: 16570675
Drug: Miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole nitrate 0.25% ointment
Study: 10030325
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (diuretics, beta‐blockers)
Study: 7946181
Drug: Isradipine monotherapy
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine monotherapy
Study: 8767350
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Isradipine + metoprolol/enalapril)
Study: 1879388
Drug: Social-influences-based drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social-influences-based drug prevention program (Midwestern Prevention Project)
Study: 30019634
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 100 mg/day plus intensive blood pressure treatment (targeted systolic blood pressure < 120 mmHg, monitored with a home blood pressure measuring device)
Study: 28490022
Drug: COPE (Concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPE (Concurrent Treatment with Prolonged Exposure)
Study: 28490022
Drug: RPT (Relapse
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPT (Relapse Prevention Therapy)
Study: 21131371
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 125 mg i.v.
Study: 17022853
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg b.i.d. with Metformin 1000 mg b.i.d.
Study: 17022853
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg b.i.d. with Sitagliptin placebo
Study: 17022853
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg b.i.d. with Metformin placebo
Study: 17022853
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of Sitagliptin and Metformin
Study: 14618553
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 mg/d, flexibly dosed to 5-20 mg/d)
Study: 14618553
Drug: Haloperidol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5 mg/d, flexibly dosed to 5-20 mg/d)
Study: 9589926
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy and aspirin (group I, n = 15)
Study: 9589926
Drug: Aspirin only
Normalized name: Aspirin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin only (group II, n = 49)
Study: 8227340
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor I (IGF-I) 10 micrograms/kg.h
Study: 31868008
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional analgesic treatment)
Study: 26874683
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT-Cognitive Only)
Study: 25385727
Drug: Amrubicin 40
Normalized name: valrubicin 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrubicin 40 mg/m² IV on days 1 to 3
Study: 25385727
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m² IV on days 1 to 5
Study: 20578378
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at Shenshu (BL 23), Qihaishu (BL 24), Dachangshu (BL 25), and Pishu (BL 20) for 2 weeks
Study: 20578378
Drug: Basic neurology
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic neurology therapies (Control group)
Study: 16891991
Drug: Pamidronate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate infusion therapy
Study: 10950398
Drug: Blinded study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blinded study drug alone
Study: 10950398
Drug: Blinded drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded drug plus hydrochlorothiazide (HCTZ)
Study: 10950398
Drug: Blinded drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded drugs plus HCTZ and additional drugs
Study: 8978804
Drug: 5'-DFUR (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'-DFUR (1,200 mg/day) administered preoperatively for 7 to 14 days
Study: 3519193
Drug: Prophylactic endoscopic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic endoscopic paravariceal injection sclerotherapy (group IB)
Study: 3519193
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (group IA)
Study: 3519193
Drug: Prophylactic endoscopic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic endoscopic paravariceal injection sclerotherapy (group II)
Study: 3519193
Drug: Regular monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular monitoring and re-injection (group II)
Study: 15659494
Drug: DF (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DF (docetaxel 75 mg/m(2) day 1, fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)
Study: 15659494
Drug: ECF (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECF (epirubicin 50 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)
Study: 3181098
Drug: Riboflavin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin (200 mg), retinol (15 mg), and zinc (50 mg) supplement
Study: 11773179
Drug: Ranpirnase (Onconase;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranpirnase (Onconase; Alfacell Corp, Bloomfield, NJ), single weekly intravenous dose
Study: 27438182
Drug: Aripiprazole addition
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole addition (adding aripiprazole to previous antipsychotics)
Study: 27438182
Drug: Aripiprazole switching
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole switching (switching previous antipsychotics to aripiprazole)
Study: 22507886
Drug: ω‐3 fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 fatty acids (1350 mg of eicosapentaenoic acid and 850 mg of docosahexaenoic acid daily)
Study: 21409920
Drug: Brand 'A'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand 'A' clopidogrel 600 mg
Study: 21409920
Drug: Brand 'B'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand 'B' clopidogrel 600 mg
Study: 17961722
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy followed by autologous transplantation of hematopoietic stem cells (HDT/ASCT)
Study: 11950190
Drug: Oestrogen treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen treatment (oestradiol valerate 2mg once daily)
Study: 9585678
Drug: Clarithromycin group
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin group (amoxicillin 1000 mg twice daily, omeprazole 20 mg twice daily, clarithromycin 250 mg twice daily)
Study: 9585678
Drug: Metronidazole group
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole group (amoxicillin 1000 mg twice daily, omeprazole 20 mg twice daily, metronidazole 500 mg twice daily)
Study: 8607304
Drug: Topical tonsillar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tonsillar spray with 10% lidocaine 4 mg kg‐1 3 minutes before surgical incision
Study: 8607304
Drug: Topical tonsillar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tonsillar spray with 10% lidocaine after both tonsils had been removed
Study: 8607304
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical spray (control group)
Study: 8607304
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (both pre- and postoperative)
Study: 2744908
Drug: Symmetric dosing
Normalized name: amantadine hydrochloride Oral Solution [Symmetrel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symmetric dosing with sustained-release theophylline (450 mg b.i.d.)
Study: 2744908
Drug: Asymmetric dosing
Normalized name: An asymmetric immunoglobulin G1 (IgG1)-based, B-cell maturation antigen (BCMA) x CD3 T-cell bispecific monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asymmetric dosing with sustained-release theophylline (270 mg plus 630 mg)
Study: 6125195
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg pindolol
Study: 31831564
Drug: Selinexor (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (60 mg oral) with Gemcitabine (1,000 mg/m2 i.v.) and Nab-Paclitaxel (125 mg/m2 i.v.)
Study: 31831564
Drug: Selinexor-GEM-nab-paclitaxel combination
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Selinexor-GEM-nab-paclitaxel combination
Study: 23455386
Drug: Arthroscopy-guided suprascapular
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopy-guided suprascapular nerve block using 10 mL 0.5 % ropivacaine with 1:200,000 epinephrine
Study: 23455386
Drug: Placebo using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo using 10 mL 0.9 % saline
Study: 21725239
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg) and Control
Study: 16469019
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg CR oxybutynin
Study: 16469019
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg CR oxybutynin
Study: 16469019
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg CR oxybutynin
Study: 15117983
Drug: CMF-->DOX (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF-->DOX (four courses of full-dose DOX followed by eight courses of i.v. CMF)
Study: 9429741
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium (MK-0476), 10 mg d-1 for 7 days
Study: 9429741
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium (MK-0476), 7 mg intravenous (5 min infusion)
Study: 9429741
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium (MK-0476), 10 mg oral dose
Study: 8381624
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) 10 mg
Study: 8381624
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (NED) 10 mg
Study: 27450091
Drug: Whole-flock treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-flock treatment with tilmicosin and enhanced biosecurity
Study: 21029674
Drug: Alprostadil injection
Normalized name: alprostadil Injection
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil injection (10 µg i.v. once every 12 hours for 7 days)
Study: 21029674
Drug: Alprostadil injection
Normalized name: alprostadil Injection
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil injection
Study: 15797147
Drug: Nurse administered
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse administered intervention
Study: 10489912
Drug: Pancrelipase capsules
Normalized name: Pancrelipase Capsules
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancrelipase capsules
Study: 1835661
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion 5‐fluorouracil plus cisplatin
Study: 1835661
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methotrexate plus 5‐fluorouracil plus adriamycin (FAMTX)
Study: 7034916
Drug: Bumetanide, 2
Normalized name: Bumetanide, 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide, 2 to 6 mg/d
Study: 7034916
Drug: Furosemide, 40
Normalized name: Furosemide, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide, 40 to 160 mg/d
Study: 24876430
Drug: Test Meter
Normalized name: prothrombin time/INR test meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Meter with in-built insulin calculator
Study: 24876430
Drug: Usual method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual method of testing blood glucose and deciding insulin doses
Study: 22577270
Drug: Probiotic complex
Normalized name: RITE AID Probiotic Complex Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic complex containing B. bifidum, L. acidophilus, L. casei, and L. salivarius for 8 weeks
Study: 19229814
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus renal artery stenting (angioplasty group)
Study: 19229814
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (drug therapy group)
Study: 15064916
Drug: Olanzapine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-10 mg/day, once or twice daily)
Study: 15064916
Drug: Fluphenazine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine (5-10 mg/day, once or twice daily)
Study: 11870677
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg tablet (test formulation)
Study: 11870677
Drug: Norvasc 5
Normalized name: Norvasc 5mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norvasc 5 mg tablet (reference formulation)
Study: 8170179
Drug: Primary coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary coronary angioplasty without prior thrombolytic therapy
Study: 8170179
Drug: Immediate adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate adjunctive angioplasty after thrombolytic therapy
Study: 8170179
Drug: Rescue angioplasty
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue angioplasty after failed thrombolytic therapy
Study: 8170179
Drug: Deferred adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred adjunctive angioplasty during the weeks after infarction
Study: 3342656
Drug: MDI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI with InspirEase (3 puffs of metaproterenol 0.65 mg/puff) plus nebulizer with placebo
Study: 3342656
Drug: Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDI with InspirEase plus nebulizer with 15 mg metaproterenol
Study: 2041147
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg OFLX (twice daily)
Study: 2041147
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg OFLX (twice daily)
Study: 2041147
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg OFLX (twice daily)
Study: 2041147
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg OFLX (twice daily)
Study: 25989270
Drug: FOLFIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI plus pimasertib (45 mg/day)
Study: 25989270
Drug: FOLFIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI plus pimasertib (60 mg/day)
Study: 11580742
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with six monthly depot injections of leuprolide acetate (LA)
Study: 11580742
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment with two monthly LA injections
Study: 3107601
Drug: Nalbuphine 20
Normalized name: nalbuphine 20 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 20 mg i.v.
Study: 19379147
Drug: Oral hypoglycemic
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemic agents (OHAs)
Study: 29395308
Drug: Collagen-fibrin patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen-fibrin patch
Study: 25928620
Drug: Adaptive servo-ventilation
Normalized name: Servo Stat Bac
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adaptive servo-ventilation (ASV) therapy for 24 weeks along with guideline-directed medical therapy
Study: 25928620
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapy for 24 weeks
Study: 8561762
Drug: Fear of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fear of flying and fear of injections as a function of age in women
Study: 6337491
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of Cefoxitin
Study: 25030722
Drug: Pregabalin and
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin and nonsteroidal anti-inflammatory drug combination therapy
Study: 25030722
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drug monotherapy
Study: 23165739
Drug: 5‐HT (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT (50 µg)
Study: 23165739
Drug: Histamine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (0.2 µg)
Study: 12875586
Drug: Phenoxybenzamine (alpha-sympathetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoxybenzamine (alpha-sympathetic blocking agent) applied to nasal mucosa
Study: 10442799
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg, n = 184)
Study: 10442799
Drug: Amitriptyline (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50-100 mg, n = 191)
Study: 7790289
Drug: Program L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program L (low stimulation)
Study: 467482
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN), 5 mg, sublingually
Study: 467482
Drug: Nifedipine (N),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (N), 10 mg, orally
Study: 467482
Drug: Verapamil (V),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (V), 160 mg, orally
Study: 467482
Drug: Propranolol (Pr),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (Pr), 40 mg, orally
Study: 21871667
Drug: Short-Term Therapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-Term Therapy
Study: 19356391
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 1200 mg once daily for 6 days
Study: 19356391
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride 850 mg single-dose
Study: 18193500
Drug: Poly-L-lactic acid
Normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly-L-lactic acid (PLA) injections administered every 2 weeks for 4 treatments
Study: 18193500
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (deferred PLA treatment)
Study: 9747746
Drug: Intravenous IL-2
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous IL-2 (9 Mio I.U. per day)
Study: 9747746
Drug: Subcutaneous IL-2
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous IL-2 (9 Mio I.U. per day)
Study: 9747746
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Intravenous and Subcutaneous IL-2)
Study: 8878381
Drug: FK506 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK506 (low trough level 5-14 ng/ml)
Study: 8878381
Drug: FK506 (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK506 (medium trough level 15-25 ng/ml)
Study: 8878381
Drug: FK506 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK506 (high trough level 26-40 ng/ml)
Study: 2265113
Drug: hM-CSF (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: hM-CSF (2 x 10(5) units/kg daily from day 1 to day 14 after BMT)